GE Healthcare Patent-Cliff Exposure & CMS Drug Spending Portfolio

GE Healthcare (US): 9 reconciled FDA prescription therapies, $119.5M 2024 CMS Part D & Medicaid spend, and 3 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies9
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2028-01-01
2024 CMS Total Public Spend$119.5M
2024 Medicare Part D Spend$0
2024 Medicaid Spend$119.5M
California HCAI SB 17 Filings3 WAC filings (max 27.3% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for GE HealthCare across sibling Meru public-data platforms.